牛牛AI助理已提取核心訊息
SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorders and rare diseases, has advanced its acquisition process of a leading vehicle importer in Israel by providing a bridge loan of $1.4 million. The loan agreement, signed on January 16, 2024, is part of the ongoing negotiations following a non-binding letter of intent announced on November 22, 2023, and additional terms disclosed on December 7, 2023. SciSparc intends to acquire 100% of the target company and create a new wholly-owned Israeli subsidiary to merge with the target. Post-acquisition, SciSparc shareholders are expected to own approximately 50.01% of the combined entity. The bridge loan, bearing an annual interest rate of 7% (or 9% if the acquisition is not completed by the repayment date), is set to...Show More
SciSparc Ltd., a clinical-stage pharmaceutical company specializing in central nervous system disorders and rare diseases, has advanced its acquisition process of a leading vehicle importer in Israel by providing a bridge loan of $1.4 million. The loan agreement, signed on January 16, 2024, is part of the ongoing negotiations following a non-binding letter of intent announced on November 22, 2023, and additional terms disclosed on December 7, 2023. SciSparc intends to acquire 100% of the target company and create a new wholly-owned Israeli subsidiary to merge with the target. Post-acquisition, SciSparc shareholders are expected to own approximately 50.01% of the combined entity. The bridge loan, bearing an annual interest rate of 7% (or 9% if the acquisition is not completed by the repayment date), is set to be repaid by the earlier of the acquisition closing, three months after any termination of the definitive agreement, or by July 15, 2024. The repayment will be offset against a planned $4.25 million financing provided by SciSparc upon closing. The announcement was made in a press release issued on January 19, 2024, and filed with the SEC as part of a Form 6-K report.
ScisPARC Ltd. 是一家專門研究中樞神經系統疾病和罕見疾病的臨床階段製藥公司，通過提供140萬美元的過渡貸款，推進了對以色列一家領先汽車進口商的收購進程。該貸款協議於2024年1月16日簽署，是繼2023年11月22日宣佈的不具約束力的意向書以及2023年12月7日披露的額外條款之後正在進行的談判的一部分。ScisPARC打算收購目標公司100％的股份，併成立一家新的全資以色列子公司以與目標公司合併。收購後，ScisPARC的股東預計將擁有合併後實體約50.01％的股份。過渡貸款的年利率爲7％（如果收購未在還款日之前完成，則爲9％），將在收購結束時以較早者爲準，在最終協議終止後三個月，或在2024年7月15日之前償還。這筆還款將抵消ScisPARC計劃在收盤時提供的425萬美元融資。該公告是在2024年1月19日發佈的新聞稿中宣佈的，並作爲6-K表格報告的一部分提交給美國證券交易委員會。
ScisPARC Ltd. 是一家專門研究中樞神經系統疾病和罕見疾病的臨床階段製藥公司，通過提供140萬美元的過渡貸款，推進了對以色列一家領先汽車進口商的收購進程。該貸款協議於2024年1月16日簽署，是繼2023年11月22日宣佈的不具約束力的意向書以及2023年12月7日披露的額外條款之後正在進行的談判的一部分。ScisPARC打算收購目標公司100％的股份，併成立一家新的全資以色列子公司以與目標公司合併。收購後，ScisPARC的股東預計將擁有合併後實體約50.01％的股份。過渡貸款的年利率爲7％（如果收購未在還款日之前完成，則爲9％），將在收購結束時以較早者爲準，在最終協議終止後三個月，或在2024年7月15日之前償還。這筆還款將抵消ScisPARC計劃在收盤時提供的425萬美元融資。該公告是在2024年1月19日發佈的新聞稿中宣佈的，並作爲6-K表格報告的一部分提交給美國證券交易委員會。
有用
沒用